Preclinical findings reported in the journal Cell could lead to a new type of immunotherapyContinue reading
Author Archive: AZBio
Xcellerant Ventures Ends First Year with 10th Investment, Leading CRISPR QC’s $10 Million Series A Round
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Xcellerant Ventures is proud to announce its investment in CRISPR QC, the San Diego-based biotechnology company that has developed the world’s first platform to precisely analyze the quality of the CRISPR/CAS9 gene editing system. By providing a way to standardize measurements for efficiency and accuracy, CRISPR QC enables pharmaceutical and agriculture companies to quickly screen for the best therapeutics to develop into next generation personalized medicines.Continue reading
$1M gift to Wildcat Philanthropic Seed Fund to provide fuel for UArizona ventures
An anonymous donor’s transformational contribution will support impactful innovation and startups that result from the work of university faculty, staff and students.Continue reading
Reglagene Receives FDA Orphan Drug Designation for Innovative Brain Cancer Treatment
New therapy crosses blood-brain barrier to give new hope to patients with rare, aggressive cancerContinue reading
Reglagene, Inc. Announces closing of $5.4 Million Private Placement
Company developing breakthrough therapies for brain diseases has closed oversubscribed private placement to fund clinical trial planning and R & D.
Inability to penetrate the blood-brain barrier has been a roadblock to treat brain diseases. Reglagene has addressed this and paves the way in therapies offering brain cancer patients new hope.” — Richard Austin, Ph.D., MBAContinue reading
Xcellerant Ventures Invests in Series A Funding Round for Lenoss Medical
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Xcellerant Ventures welcomes Lenoss Medical into our Venture Fund I portfolio. Lenoss Medical is disrupting the treatment of spinal fractures with their OsteoPearl VBA System. This minimally invasive and cement-free technology delivers a fully biologic solution to stabilize spinal fractures and utilizes the natural healing properties of healthy bone.Continue reading
University of Arizona selects design, build firms for CAMI
The University of Arizona Health Sciences announced December 12 it had selected McCarthy + SmithGroup to lead the design and construction of the Center for Advanced Molecular and Immunological Therapies, or CAMI, facility in downtown Phoenix.Continue reading
In Comments to FDA, AdvaMed Maintains Support of Agency’s Authority to Regulate LDTs
WASHINGTON, D.C. – Today, AdvaMedDx submitted comments in response to the Food and Drug Administration’s Proposed Rule: Medical Devices; Laboratory Developed Tests. AdvaMedDx is a division of AdvaMed representing companies that develop in vitro diagnostic (IVD) tests.
Avery Therapeutics, Inc. shares publication in Nature Communications Biology: “Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts”
TUCSON, ARIZONA, DECEMBER 11, 2023 – Avery Therapeutics, Inc., a privately held, pre-clinical stage therapeutics company, developing therapeutics for diseases of aging, inflammation and fibrosis announces a publication in Nature Communications Biology, dated November 24, 2023. The article, titled “Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts,” demonstrates a novel approach in the treatment of chronic heart failure (CHF).Continue reading